BioMarin is pumping the brakes on yet another indication for its CNP analogue, Voxzogo. | The rare disease biotech announced ...
In a push to free itself up for more R&D, Sanofi is acquiring a stake in German drugmaker, Cheplapharm. | In a deal that ...
The FDA has approved the industry’s very first generic radioligand therapy, known as a radioligand equivalent. | The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium ...
The agreement makes AbbVie, which reported $3.2 billion in neuroscience sales in the second quarter, the official pharmaceutical sponsor of the PGA Tour, a professional golf organization. This month’s ...
“In healthcare communications, memorability is what helps turn awareness into action,” Pooja Bhavsar, SVP, strategic planner at The Bloc, said in a statement. “Make the Call was designed to be ...
In what signifies the end of a challenging regulatory journey, Scholar Rock secured an FDA approval for its spinal muscular ...
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk. | GSK is ...
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...
A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...
The fact that Gilead Sciences’ Trodelvy failed as a first-line treatm | Newly revealed global phase 3 data from Merck and ...
Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...
The ink was barely dry on the FDA approval letter for AstraZeneca’s Etcamah before the oral SERD suffered a key clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results